Treating the Leading Causes of Blindness

Galimedix Therapeutics is a Phase 2 pharma company with a novel first-in-class drug with ground-breaking potential to slow or stop the progression of Glaucoma and dry AMD - neurodegenerative diseases and leading causes of blindness.

About Us

A Potentially Disruptive Technology

We have developed a unique first-in-class, potentially disruptive technology to treat the underlying causes of Glaucoma and Dry AMD blindness, using eye drops, as well as a next generation oral delivery version.

Our Technology

Unique Drugs for Neurodegeneration of the Eye

Our therapies are focused on slowing or stopping the progression of glaucoma and dry AMD, both being neurodegenerative diseases of the eye that are the leading causes of blindness.

Our Products

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign me up for: